Literature DB >> 9798730

Phenylephrine, endothelin, prostaglandin F2alpha' and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro.

K L King1, J Winer, D M Phillips, J Quach, P M Williams, J P Mather.   

Abstract

In these studies, we show that endothelin (ET), leukemia inhibitory factor (LIF), phenylephrine (PE), and prostaglandin F2alpha (PGF2alpha), which are all hypertrophic for neonatal rat cardiac myocytes in culture, induce distinct morphological, physiological, and genetic changes after a 48-h treatment. Transmission electron microscopy revealed differences in myofibril organization, with ET-treated cells containing the most mature-looking myofibrils and PGF2alpha- and LIF-treated cells the least. ET- and PE-treated cultures contained the same number of beating cells as control, but LIF and PGF2alpha treatment increased the number of beating cells 180%. Treatment with LIF, PE, and PGF2alpha increased the beat rate to 3.3 times that of control. After exposure to the beta-adrenergic agonist isoproterenol, the beat rate increased 50% for PGF2alpha' 54% for PE, 84% for LIF, and 125% for control. ET treatment did not increase the beat rate, nor did these cells respond to isoproterenol. ET, LIF, and PE increased the production of atrial natriuretic peptide (ANP) by three-fold and PGF2alpha by 18-fold over nontreated cells. Brain natriuretic peptide (BNP) was increased fourfold by ET and PE, 16-fold by LIF, and 29-fold by PGF2alpha. Interestingly, on a pmol/L basis, only LIF induced more BNP than ANP. Treatment with all agents led to a similar pattern of gene induction: increased expression of the embryonic genes for ANP and skeletal alpha-actin, and less than a twofold change in the constitutively expressed gene myosin light chain-2, with the exception that LIF did not induce skeletal alpha-actin. Each agent, however, induced ANP mRNA with a different time-course. We conclude that at least four distinct cardiac myocyte hypertrophy response programs can be induced in vitro. Further studies are necessary to determine whether these correlate to the different types of cardiac hypertrophy seen in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798730     DOI: 10.1385/endo:9:1:45

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  36 in total

1.  A novel method for real time quantitative RT-PCR.

Authors:  U E Gibson; C A Heid; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

2.  Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes.

Authors:  H Ito; Y Hirata; M Hiroe; M Tsujino; S Adachi; T Takamoto; M Nitta; K Taniguchi; F Marumo
Journal:  Circ Res       Date:  1991-07       Impact factor: 17.367

3.  Recording system for monitoring automaticity of heart cells in culture.

Authors:  G B Boder; R J Harley; I S Johnson
Journal:  Nature       Date:  1971-06-25       Impact factor: 49.962

4.  Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways.

Authors:  K C Wollert; T Taga; M Saito; M Narazaki; T Kishimoto; C C Glembotski; A B Vernallis; J K Heath; D Pennica; W I Wood; K R Chien
Journal:  J Biol Chem       Date:  1996-04-19       Impact factor: 5.157

5.  Gene expression in cardiac hypertrophy.

Authors:  K R Boheler; K Schwartz
Journal:  Trends Cardiovasc Med       Date:  1992 Sep-Dec       Impact factor: 6.677

Review 6.  Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure.

Authors:  O E Brodde; M C Michel; H R Zerkowski
Journal:  Cardiovasc Res       Date:  1995-10       Impact factor: 10.787

7.  Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by alpha1-adrenergic stimulation.

Authors:  O Nakagawa; H Itoh; M Harada; Y Komatsu; T Yoshimasa; K Nakao
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1995-12

8.  Possible involvement of endothelin-1 in cardiac hypertrophy.

Authors:  R Yorikane; S Sakai; T Miyauchi; T Sakurai; K Goto
Journal:  Arzneimittelforschung       Date:  1994-03

9.  Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy.

Authors:  D Pennica; K L King; K J Shaw; E Luis; J Rullamas; S M Luoh; W C Darbonne; D S Knutzon; R Yen; K R Chien
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

Review 10.  Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response.

Authors:  K R Chien; K U Knowlton; H Zhu; S Chien
Journal:  FASEB J       Date:  1991-12       Impact factor: 5.191

View more
  5 in total

1.  Clenbuterol induces cardiac myocyte hypertrophy via paracrine signalling and fibroblast-derived IGF-1.

Authors:  Pankaj K Bhavsar; Nigel J Brand; Leanne E Felkin; Pradeep K Luther; Martin E Cullen; Magdi H Yacoub; Paul J R Barton
Journal:  J Cardiovasc Transl Res       Date:  2010-06-25       Impact factor: 4.132

2.  Fibroblast growth factor-2 mediates pressure-induced hypertrophic response.

Authors:  J E Schultz; S A Witt; M L Nieman; P J Reiser; S J Engle; M Zhou; S A Pawlowski; J N Lorenz; T R Kimball; T Doetschman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload.

Authors:  Norifumi Takeda; Ichiro Manabe; Yuichi Uchino; Kosei Eguchi; Sahohime Matsumoto; Satoshi Nishimura; Takayuki Shindo; Motoaki Sano; Kinya Otsu; Paige Snider; Simon J Conway; Ryozo Nagai
Journal:  J Clin Invest       Date:  2009-12-21       Impact factor: 14.808

4.  Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling.

Authors:  Norifumi Takeda; Ichiro Manabe
Journal:  Int J Inflam       Date:  2011-09-18

5.  Mesenchymal-endothelial transition-derived cells as a potential new regulatory target for cardiac hypertrophy.

Authors:  Wenyan Dong; Ruiqi Li; Haili Yang; Yan Lu; Longhai Zhou; Lei Sun; Dianliang Wang; Jinzhu Duan
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.